Keller Rohrback is pleased to announce that partner David Ko has been appointed Interim Co-Lead Counsel in In re GoodRx and Pharmacy Benefits Manager Antitrust Litigation (No. II) by the Honorable Mary S. McElroy of the United States District Court for the District of Rhode Island.

The plaintiffs are a proposed class of pharmacies alleging an unlawful horizontal price-fixing agreement between GoodRx and four pharmacy benefit managers that control approximately two-thirds of the prescription market in the country: CVS Caremark, Express Scripts, MedImpact, and Navitus. Through the GoodRx Integrated Savings Program (ISP), the plaintiffs allege defendants coordinate the exchange of competitively sensitive information and impose a single, uniform “lowest negotiated rate” for every generic drug claim. This unlawful agreement suppresses reimbursement prices paid to pharmacies for generic prescription drugs, unfairly inflating defendants’ profits.

"I am honored to serve as Interim Co-Lead Counsel in this important case," said David Ko. "Independent pharmacies play a critical role in communities across the country, and we look forward to advocating on their behalf and challenging practices that undermine fair competition."

David will serve in this leadership role alongside Heidi Silton of Lockridge Grindal Nauen PLLP and Donald Migliori of Motley Rice LLC.

Congratulations to David on this well-earned appointment and his continued commitment to ensuring accountability in the healthcare marketplace.